arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

EDAP TMS SA

FOCL
$4.22 ▼ -0.07 (-1.63%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
17 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

EDAP TMS SA faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $158.4M
Dividend Yield —
Revenue Growth 38.8% ↗
Op. Margin -60.8% ↘
ROIC -23.1% ↗
FCF / Share $-0.10 ↘
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity -12.37
info Valuation on last close. End-of-day price, Nov 5, 2026.

17-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$13.20M
↑ +38.8% —
Net Income Profit after all expenses
$-14.49M
↓ -126.1% —
Operating Margin Operating profit as % of sales
-60.8%
↓ -47.1% 7th
FCF / Share Free cash flow per share
$-0.10
↑ +21.8% —
Long-Term Debt Long-term obligations
$38.05M
↑ +99.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
7
Returns ↓
5
Financial Health ↑
21
Cash Quality ↓
42

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 15 years · 17 quarters